Results 161 to 170 of about 205,750 (304)
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen +20 more
wiley +1 more source
Tumor-Associated Macrophage Polarization in Wilms' Tumor After Neoadjuvant Chemotherapy. [PDF]
Malić Tudor K +9 more
europepmc +1 more source
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold +12 more
wiley +1 more source
The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer. [PDF]
Chen Y +7 more
europepmc +1 more source
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner +16 more
wiley +1 more source
Obesity and Tolerance to Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Cohort Study. [PDF]
Machado MS +11 more
europepmc +1 more source
Abstract Objective To investigate the role of ST3 β‐galactoside α‐2,3‐sialyltransferase 1 (ST3Gal1) and vascular endothelial growth factor receptor 2 (VEGF‐R2) in endometrioid‐type epithelial ovarian cancer (E‐OC) because aberrant α2,3‐sialylation mediated by ST3Gal1 and VEGF‐R2‐related angiogenesis is linked with tumor progression. Methods ST3Gal1 and
Wei‐Ting Chao +5 more
wiley +1 more source
M2 macrophages predict response to neoadjuvant chemotherapy in triple negative breast cancer patients. [PDF]
Chen WX +7 more
europepmc +1 more source
Clinical phases and classification of breast tumor dormancy. Tumor dormancy is described as the period after treatment until residual tumor cells become detectable as relapsing disease in clinic. During the period of clinical tumor dormancy, tumor mass dormancy and cellular dormancy may coexist.
Shu Chen +4 more
wiley +1 more source
Dynamic changes of the immune microenvironment in ovarian cancer following neoadjuvant chemotherapy. [PDF]
Wu M +6 more
europepmc +1 more source

